Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists

Novel A3 adenosine antagonists available for licensing. A3 receptors are particularly highly expressed in inflammatory cells, making it a potentially desirable target for inflammatory diseases. This technology relates to highly specific antagonists and partial agonists of A3 adenosine receptors, which are negatively coupled to adenylate cyclase and have been broadly implicated in inflammation, cardiovascular disease, endocrine conditions and cancer. Further, A3 adenosine receptors have been implicated in asthma and glaucoma.

Related Invention(s):


Kenneth Jacobson (NIDDK)  ➽ more inventions...

Intellectual Property:
US Pat: 8,796,291 issued 2014-08-05
PCT Application No. PCT/US2009/52439 filed on 2009-07-31
US Application No. 13/056,997 filed on 2011-03-18

Melman A, et al. Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem. 2008 Sep 15;16(18):8546-56. PMID 18752961

Collaboration Opportunity:

The NIDDK, Laboratory of Bioorganic Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A3 adenosine receptor antagonists. Please contact Kenneth A. Jacobson, Ph.D. at or Marguerite Miller at for more information.

Licensing Contact:
Betty Tong, Ph.D.
Phone: 301-451-7836

OTT Reference No: E-285-2008-0
Updated: Sep 8, 2016